CMPX (STOCKS)
Compass Therapeutics, Inc. Common Stock
$2.010000
-0.020000 (-0.99%)
Prev close: $2.030000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Thomas J. Schuetz
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $365.58M
- Employees
- 35
- P/E (TTM)
- -4.96
- P/B (TTM)
- 1.96
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
10
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.10 | $-0.10 | +0.0001 | +0.10% |
|
Dec 2025 (Q4)
|
$-0.09 | $-0.09 | +0.0022 | +2.39% |
|
Sep 2025 (Q3)
|
$-0.08 | $-0.14 | +0.0603 | +42.98% |
|
Jun 2025 (Q2)
|
$-0.14 | $-0.12 | -0.0153 | -12.27% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $75.17M |
| Depreciation and Amortization | $151.00K |
| Research and Development | $56.30M |
| Other Operating Expenses | $18.84M |
| Operating Income/Loss | -$75.17M |
| Income/Loss From Continuing Operations After Tax | -$68.17M |
| Income/Loss From Continuing Operations Before Tax | -$68.17M |
| Net Income/Loss | -$68.17M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$68.17M |
| Net Income/Loss Available To Common Stockholders, Basic | -$68.17M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.40 |
| Basic Average Shares | 502,614,000 |
| Assets | $205.17M |
| Current Assets | $195.69M |
| Noncurrent Assets | $9.48M |
| Fixed Assets | $169.00K |
| Other Non-current Assets | $9.31M |
| Liabilities | $18.70M |
| Current Liabilities | $10.28M |
| Accounts Payable | $906.00K |
| Other Current Liabilities | $9.37M |
| Noncurrent Liabilities | $8.42M |
| Equity | $186.47M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $186.47M |
| Liabilities And Equity | $205.17M |
| Net Cash Flow From Operating Activities | -$53.20M |
| Net Cash Flow From Operating Activities, Continuing | -$53.20M |
| Net Cash Flow From Investing Activities | -$66.47M |
| Net Cash Flow From Investing Activities, Continuing | -$66.47M |
| Net Cash Flow From Financing Activities | $133.79M |
| Net Cash Flow From Financing Activities, Continuing | $133.79M |
| Net Cash Flow | $14.12M |
| Net Cash Flow, Continuing | $14.12M |
| Comprehensive Income/Loss | -$68.54M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$68.52M |
| Other Comprehensive Income/Loss | -$48.66M |